Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript

Steve Lisi: Well, we’ve done four studies already in pneumonia, three in infants and one in adults during the pandemic. So, you’re going to see pretty much what you saw there. You’re going to see safety, which will have to be the primary endpoint in a pilot study, of course, safety, tolerability and then you’ll see our efficacy endpoints will be there as well. Same efficacy endpoints you saw in the other studies. We have them on our website. They’ve been published at medical conferences as well as journals. So, you’re going to see the same thing. You’re going to see, these patients improving faster than if they don’t have nitric oxide in general. Again, this will be the fifth time we’ve done it. So, I think anybody would be shocked that you go four for four. You’re probably going to go five for five. So, if you’re going to want to take a look at our previous results, you’ll know what’s coming.

Matt Kaplan: So, just a follow up on that. So, the goal of this study is to generate data that you can take to FDA to get clearance to a pivotal or what do you hope to show?

Steve Lisi: Yeah, this would be the final study before we go into a registration study. That’s correct. The next study will be a registration study in the United States.

Matt Kaplan: Oh, great. Great. Thanks, Steve.

Operator: There are no further questions at this time. I would like to turn the floor back over to Steve Lisi for closing comments.

Steve Lisi: Yeah, thanks everybody for joining today. Internally here, we’re very positive on our outlook. We wouldn’t have put that guidance out there and as Matt mentioned on the last question, we’re very excited about our pneumonia program. Just one last note on that, it is a seasonal condition. So, these studies do move quickly. So, with that, I will say thanks again and talk to you soon.

Operator: This concludes today’s conference. Thank you for joining us. You may now disconnect your lines.